Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). Our world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing novel cancer therapies to market. A science-first mindset and patient-centric approach is in our genes. With a growing pipeline of studies, we remain dedicated to developing products for cancers with mTOR pathway driver alterations. For more information, please visit: https://aadibio.com/